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Abstract
Laboratory investigations of hypercalcemia involve testing of various biochemical parameters such as parathyroid hormone (PTH), 25-(OH) Vitamin 
D (25-(OH) VitD), 1,25-(OH)2 Vitamin D3 (calcitriol) and PTH related peptide (PTHrp).
We herein present an atypical case of severe hypercalcemia in a patient with rheumatoid arthritis who has been treated for years by various biolo-
gical disease-modifying antirheumatic drugs (DMARDs) and suddenly presented with general state alteration, oedema and ulceration of her right 
ankle. 
We illustrate how tuberculosis (TB) can cause high calcitriol concentration and subsequently lead to potentially severe hypercalcemia. Moreover, we 
highlight the importance of TB testing and follow-up in patients treated with biological DMARDs.
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Introduction
From the laboratory perspective, investigations in 
the course of de novo or chronic hypercalcemia re-
quire the use of various assays for the differential 
diagnosis between primary hyperparathyroidism, 
multiple myeloma, familial hypercalcemia, malig-
nancy, Vitamin D (VitD) intoxication or granuloma-
tosis. The most frequently used tests for this 
workup besides calcemia are: parathyroid hor-
mone (PTH), PTH related peptide (PTHrp), 25-(OH) 
Vitamin D (25-(OH) VitD), and 1,25-(OH)2 Vitamin 
D3 (calcitriol) (1,2). 
Tuberculosis (TB) in its pulmonary and disseminat-
ed forms is known to be a rare but well-described 
cause of hypercalcemia and is described to be as-
sociated with high concentrations of calcitriol (3–
5). Here, we report the case of hypercalcemia in a 
patient with disseminated TB and articular presen-
tation, in the context of long-term treatment of 
rheumatoid arthritis (RA) by biological disease-
modifying antirheumatic drugs (DMARDs). 
Case presentation
The patient was a 67-year-old Caucasian female 
who has been consulting in the rheumatology de-
partment at our facility in the course of an erosive 
seropositive RA, which was poorly evolving. 
Among other medications, the patient was treated 
for several years with different DMARDs, such as 
etanercept and more recently with infliximab and 
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then tocilizumab, together with methotrexate. At 
her last outpatient visit, hospitalization was 
planned as her inflammatory disease was worsen-
ing and associated with general state alteration, 
fever, mild dyspnoea as well as seemingly chronic 
oedema and ulceration of her right ankle articula-
tion. Her routine blood examination, from which 
relevant biochemistry results are summarized in 
Table 1, showed increased C-reactive protein con-
centrations (CRP) to 114.2 mg/L (upper reference 
limit (URL): 5 mg/L), concordant with her active in-
flammatory pathology, acute renal failure (creati-
nine (CREA): 234 µmol/L (reference range (RR): 53 - 
115 µmol/L), urea: 43.9 mmol/L (RR: 5.4–17.9 
mmol/L), estimated glomerular filtration rate 
(eGFR) based on the chronic kidney disease epide-
miology collaboration (CKD-EPI) equation: 18 mL/
min/1.73m2 (lower reference limit: 60 mL/
min/1.73m2) and open hypercalcemia (total calci-
um (Ca) concentration: 4.38 mmol/L (RR: 2.20–2.55 
mmol/L), confirmed with a clearly increased albu-
min-corrected Ca of 4.43 mmol/L (RR: 2.20–2.55 
mmol/L)). This led to anticipated hospitalization. 
The patient signed an informed consent form for 
anonymous publication of medical data. 
Clinical and laboratory investigations
The clinician’s investigations included first suspi-
cion of multiple myeloma as age, renal function 
and calcemia were suggestive of such pathology. 
However, neither serum protein electrophoresis 
nor immunoglobulins and free light chains assay 
nor urine immunofixation showed the presence of 
monoclonal immunoglobulin. Urinalysis exhibited 
no significant features.
Besides, as intact PTH concentration was 14 ng/L 
(RR: 15–80 ng/L), hyperparathyroidism and familial 
hypercalcemia were excluded. PTHrp concentra-
tion was < 20 ng/L (URL: 20 ng/L), excluding a neo-
plastic origin for the high Ca concentration ob-
served. 
Notably, 25-(OH) VitD concentration was 88 
nmol/L (RR: 75–250 nmol/L) but calcitriol concen-
tration was interestingly high (171 pg/mL (RR: 20–
79 pg/mL), suggesting pathologies such as lym-
phoma or granulomatous diseases such as sar-
coidosis and tuberculosis. Various assays were 
used to perform differential diagnosis. Urine Ca 
normalized for urine CREA was 2.26 mM/mM (URL: 
Parameter Observed concentration Reference range
CRP (mg/L) 114.2 < 5
Urea (mmol/L) 43.9 5.4-17.9
CREA (µmol/L) 234.3 53-115
eGFR (CKD-EPI) (mL/min/1.73m2) 18 > 60
Sodium (mmol/L) 137 135-145
Potassium (mmol/L) 3.96 3.5-5
Phosphate (mmol/L) 1.76 0.81-1.45
Total calcium (mmol/L) 4.38 2.20-2.55
Albumin-corrected calcium (mmol/L) 4.43 2.20-2.55
Albumin (g/L) 38 35-52
Intact PTH (ng/L) 14 15-80
PTHrp (ng/L) < 20 < 20
25-(OH) VitD (nmol/L) 87.5 75-250
1,25-(OH)2 Vitamin D3 (pg/mL) 171 20-79
CRP – C-reactive protein. CREA – creatinine. eGFR – estimated glomerular filtration rate. CKD-EPI – chronic kidney disease 
epidemiology collaboration equation. PTH – parathyroid hormone. PTHrp – PTH related peptide. 25-(OH) VitD – 25-(OH) vitamin D.
Table 1. Relevant biochemistry results at time of hospitalization
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0.40 mM/mM) and showed hypercalciuria. Angio-
tensin converting enzyme activity was 68 U/L (RR: 
12–68 U/L) and blood lysozyme was 131.4 mg/L 
(RR: 9.6 –17.1 mg/L) (increased around 8 times the 
upper limit of the reference range). 
The final diagnosis was achieved by performing a 
further examination of the patient’s right ankle. 
Radiography and magnetic resonance imaging 
showed active multifocal osteoarthritis while posi-
tron emission tomography-computed tomogra-
phy showed multiple hypermetabolic lesions at 
the pericardial, periarticular, muscular, meningeal, 
and lymph nodes hypermetabolic lesions and also 
revealed wide pulmonary cavities. Microbiological 
samples were collected as surgery was performed 
and were sent to our bacteriology laboratory for 
culture and Koch’s bacillus research. Microscopic 
examination of auramine-stained slides showed 
the presence of acid-fast bacilli, which was also de-
tected by a semi-quantitative nested polymerase 
chain reaction. Culture on liquid medium further-
more confirmed positivity for Mycobacterium tu-
berculosis complex and further identification of 
Mycobacterium bovis was performed by Sciensano 
(National Reference Center for the diagnosis of tu-
berculosis and human mycobacterioses, Brussels, 
Belgium) 
Treatment and outcome 
Hypercalcemia and acute renal failure were treat-
ed in the emergency room by the administration 
of large amounts of sodium chloride, 40 mg furo-
semide, and 90 mg pamidronate. This temporarily 
decreased albumin-corrected Ca concentration to 
2.80 mmol/L, which nonetheless stayed above our 
institution’s reference range (2.20–2.55 mmol/L) 
for days after the patient was taken care of. Tuber-
culosis was treated by classical 4-drugs therapy (ri-
fampin, isoniazid, pyrazinamide, ethambutol + 
pyridoxine) until antibiogram and formal identifi-
cation suggested stopping pyrazinamide because 
of resistance. 
Normalization of eGFR to 63 mL/min/1.73m2 was 
not achieved before one week after antibiotic 
treatment onset and total Ca concentration to 2.35 
mmol/L (RR: 2.20–2.55 mmol/L) (no albumin-cor-
rected value available at that time point) was doc-
umented one week later. Ulceration and oedema 
of the ankle also started healing at the same time, 
initiating a slow recovery of the wound.
Usual RA treatment was suspended and limited to 
daily 7.5 mg prednisolone. Tocilizumab treatment 
was planned to be resumed when infectious 
symptoms would be under control.
Discussion 
Hereby, we described an unusual case of hypercal-
cemia in the context of disseminated TB in a pa-
tient with RA treated by biological DMARDs. The 
patient displayed increased calcitriol concentra-
tion and normal 25-(OH) VitD whereas PTH con-
centration was decreased and PTHrp was within 
the reference range. The diagnosis of TB was later 
confirmed by clinical and microbiological investi-
gations and concluded to mycobacterial infection. 
Biochemical results were consistent with previous 
reports of such cases of TB-induced hypercalcemia 
(6,7). In this particular context of TB-induced hy-
percalcemia, a first hypothesis for the Ca raise 
could be the high calcitriol concentrations, leading 
to an increased intestinal Ca absorption and oste-
oclastic bone resorption (3–5). Such an increase in 
calcitriol concentrations can be linked to a trig-
gered 1-α-hydroxylase activity of the macrophag-
es within the granulomatous reaction sites of pa-
tients presenting TB or sarcoidosis (8). 
Additionally, another interesting hypothesis could 
be the activation/reactivation of TB, and its related 
impact on Ca concentrations, in the context of RA, 
handled by long-term anti-TNFα and then IL-6 an-
tagonist treatment. The mechanism of action of 
both treatments target inflammatory cytokines 
and therefore are well-described causes of latent 
TB reactivation or primary TB infection (9-11). 
These cytokines are indeed involved in the immu-
no-inflammatory response to mycobacterial infec-
tions (12,13). This major adverse effect of these bio-
logical DMARDs is known to be higher with etaner-
cept than with other treatments and is further-
more not only described in TB but also in nontu-
berculous mycobacteria infections (14,15).
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Our study has several limitations. A first one is the 
lack of measurement of an ionized-Ca assay, a ref-
erence method to confirm hypercalcemia that dis-
plays higher sensitivity and specificity than total 
Ca (2). However, the hypercalcemia of our case was 
confirmed by albumin-corrected Ca. A second lim-
itation could be the start of the biological DMARDs 
treatment in another care setting, unknown to the 
authors, misleading the information of an initial 
screening for TB in our patient in this facility. 
This case is yet another proof of the importance of 
TB screening and follow-up in patients treated 
with anti-TNFα and non-anti-TNFα treatments. 
In conclusion, this case illustrates how granuloma-
tosis and by extension, TB, can cause potentially 
severe hypercalcemia. This was described to be as-
sociated with a granulomatosis-triggered increase 
in calcitriol concentration. Moreover, we highlight 
the importance of TB monitoring in patients treat-
ed by anti-TNFα or non-anti-TNF biological 
DMARDs in order to prevent infection or reactiva-
tion. 
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